Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody therapies for psoriasis and other inflammatory conditions. Its lead products, ORKA-001 and ORKA-002, target IL-23 and IL-17 cytokines, respectively, aiming to improve efficacy and reduce dosing frequency. With a significant market opportunity in the $25 billion psoriasis market, Oruka is positioned to address unmet needs through advanced antibody engineering and strategic partnerships.
This description was generated via AI from an annual report. Updated about 1 year ago.